5-Hydroxyhexanoic Acid Predicts Early Renal Functional Decline in Type 2 Diabetes Patients with Microalbuminuria
Background/Aims: Diabetic nephropathy (DN) is a leading cause of end-stage renal disease. Microalbuminuria (MA) is widely used to predict early progressive renal function decline (ERFD) of DN in type 2 diabetes mellitus (T2D) patients, but the sensitivity and specificity of MA have been questioned....
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2019-05-01
|
| Series: | Kidney & Blood Pressure Research |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/498962 |
| _version_ | 1818309433361432576 |
|---|---|
| author | Xiaofang Tang Jing You Di Liu Ming Xia Liyu He Hong Liu |
| author_facet | Xiaofang Tang Jing You Di Liu Ming Xia Liyu He Hong Liu |
| author_sort | Xiaofang Tang |
| collection | DOAJ |
| description | Background/Aims: Diabetic nephropathy (DN) is a leading cause of end-stage renal disease. Microalbuminuria (MA) is widely used to predict early progressive renal function decline (ERFD) of DN in type 2 diabetes mellitus (T2D) patients, but the sensitivity and specificity of MA have been questioned. Here, we determined the urine metabolites differences between T2D patients with MA who maintained stable renal function and those who progressed to ERFD in order to identify specific biomarkers of the progression of renal dysfunction. Methods: A total of 102 T2D patients with MA and normal renal function at baseline were followed up for 5–6 years. Of these, 52 patients were selected and classified into two groups according to the later renal function; 25 patients who experienced ERFD were regarded as the progressive group, while 27 patients who maintained stable renal function were considered as the stable group. In the pilot study, untargeted, broad-spectrum urine metabolomics was performed on the urine of 12 subjects from the progressive group (5 patients as “progressors”) and stable group (7 patients as “non-progressors”) to discover candidate markers. We then used a targeted metabolomics analysis to identify the selected markers in the urine of an additional 40 patients (20 from the progressive group as cases, and 20 from the stable group as controls) in the validation study. Results: A total of 318 known metabolites were detected in the pilot study and 6 metabolites with significant difference between progressors and non-progressors were identified. The levels of 4 metabolites, including azelaic acid, adipic acid, 5-hydroxyhexanoic acid, and L-tryptophan decreased significantly, while levels of L-pyroglutamic acid and D-norvaline increased observably in the progressors compared with non-progressors. Furthermore, in the validation study, 6 metabolites were confirmed by quantitative measurements and their concentrations were consistent with the changes in the pilot study. Concentrations of L-pyroglutamic acid and D-norvaline still increased in the cases, but were not statistically significant. Of the 4 metabolites with decreased concentrations among the cases, only 5-hydroxyhexanoic acid remained statistically significant while the other 3 metabolites did not differ between cases and controls. Conclusion: We have identified urine metabolites and shown that 5-hydroxyhexanoic acid can be used as a predictor of progression of ERFD in T2D patients with MA. This finding provides the new perspective that 5-hydroxyhexanoic acid may be useful to identify T2D patients with MA who are at risk of ERFD. |
| first_indexed | 2024-12-13T07:30:05Z |
| format | Article |
| id | doaj.art-09fb8c88cc5b42e1adc821bed0ff3d95 |
| institution | Directory Open Access Journal |
| issn | 1420-4096 1423-0143 |
| language | English |
| last_indexed | 2024-12-13T07:30:05Z |
| publishDate | 2019-05-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Kidney & Blood Pressure Research |
| spelling | doaj.art-09fb8c88cc5b42e1adc821bed0ff3d952022-12-21T23:55:13ZengKarger PublishersKidney & Blood Pressure Research1420-40961423-01432019-05-0144224526310.1159/0004989624989625-Hydroxyhexanoic Acid Predicts Early Renal Functional Decline in Type 2 Diabetes Patients with MicroalbuminuriaXiaofang TangJing YouDi LiuMing XiaLiyu HeHong LiuBackground/Aims: Diabetic nephropathy (DN) is a leading cause of end-stage renal disease. Microalbuminuria (MA) is widely used to predict early progressive renal function decline (ERFD) of DN in type 2 diabetes mellitus (T2D) patients, but the sensitivity and specificity of MA have been questioned. Here, we determined the urine metabolites differences between T2D patients with MA who maintained stable renal function and those who progressed to ERFD in order to identify specific biomarkers of the progression of renal dysfunction. Methods: A total of 102 T2D patients with MA and normal renal function at baseline were followed up for 5–6 years. Of these, 52 patients were selected and classified into two groups according to the later renal function; 25 patients who experienced ERFD were regarded as the progressive group, while 27 patients who maintained stable renal function were considered as the stable group. In the pilot study, untargeted, broad-spectrum urine metabolomics was performed on the urine of 12 subjects from the progressive group (5 patients as “progressors”) and stable group (7 patients as “non-progressors”) to discover candidate markers. We then used a targeted metabolomics analysis to identify the selected markers in the urine of an additional 40 patients (20 from the progressive group as cases, and 20 from the stable group as controls) in the validation study. Results: A total of 318 known metabolites were detected in the pilot study and 6 metabolites with significant difference between progressors and non-progressors were identified. The levels of 4 metabolites, including azelaic acid, adipic acid, 5-hydroxyhexanoic acid, and L-tryptophan decreased significantly, while levels of L-pyroglutamic acid and D-norvaline increased observably in the progressors compared with non-progressors. Furthermore, in the validation study, 6 metabolites were confirmed by quantitative measurements and their concentrations were consistent with the changes in the pilot study. Concentrations of L-pyroglutamic acid and D-norvaline still increased in the cases, but were not statistically significant. Of the 4 metabolites with decreased concentrations among the cases, only 5-hydroxyhexanoic acid remained statistically significant while the other 3 metabolites did not differ between cases and controls. Conclusion: We have identified urine metabolites and shown that 5-hydroxyhexanoic acid can be used as a predictor of progression of ERFD in T2D patients with MA. This finding provides the new perspective that 5-hydroxyhexanoic acid may be useful to identify T2D patients with MA who are at risk of ERFD.https://www.karger.com/Article/FullText/498962Diabetic nephropathyRenal function declineMetabolomics5-hydroxyhexanoic acid |
| spellingShingle | Xiaofang Tang Jing You Di Liu Ming Xia Liyu He Hong Liu 5-Hydroxyhexanoic Acid Predicts Early Renal Functional Decline in Type 2 Diabetes Patients with Microalbuminuria Kidney & Blood Pressure Research Diabetic nephropathy Renal function decline Metabolomics 5-hydroxyhexanoic acid |
| title | 5-Hydroxyhexanoic Acid Predicts Early Renal Functional Decline in Type 2 Diabetes Patients with Microalbuminuria |
| title_full | 5-Hydroxyhexanoic Acid Predicts Early Renal Functional Decline in Type 2 Diabetes Patients with Microalbuminuria |
| title_fullStr | 5-Hydroxyhexanoic Acid Predicts Early Renal Functional Decline in Type 2 Diabetes Patients with Microalbuminuria |
| title_full_unstemmed | 5-Hydroxyhexanoic Acid Predicts Early Renal Functional Decline in Type 2 Diabetes Patients with Microalbuminuria |
| title_short | 5-Hydroxyhexanoic Acid Predicts Early Renal Functional Decline in Type 2 Diabetes Patients with Microalbuminuria |
| title_sort | 5 hydroxyhexanoic acid predicts early renal functional decline in type 2 diabetes patients with microalbuminuria |
| topic | Diabetic nephropathy Renal function decline Metabolomics 5-hydroxyhexanoic acid |
| url | https://www.karger.com/Article/FullText/498962 |
| work_keys_str_mv | AT xiaofangtang 5hydroxyhexanoicacidpredictsearlyrenalfunctionaldeclineintype2diabetespatientswithmicroalbuminuria AT jingyou 5hydroxyhexanoicacidpredictsearlyrenalfunctionaldeclineintype2diabetespatientswithmicroalbuminuria AT diliu 5hydroxyhexanoicacidpredictsearlyrenalfunctionaldeclineintype2diabetespatientswithmicroalbuminuria AT mingxia 5hydroxyhexanoicacidpredictsearlyrenalfunctionaldeclineintype2diabetespatientswithmicroalbuminuria AT liyuhe 5hydroxyhexanoicacidpredictsearlyrenalfunctionaldeclineintype2diabetespatientswithmicroalbuminuria AT hongliu 5hydroxyhexanoicacidpredictsearlyrenalfunctionaldeclineintype2diabetespatientswithmicroalbuminuria |